ZLAB News and Press, Zai Lab Limited From 03/02/23

The following slide deck was published by Zai Lab Limited in conjunction with their 2022 Q4 earnings call. For further details see: Zai Lab Limited 2022 Q4 - Results - Earnings Call Presentation

Zai Lab press release ( NASDAQ: ZLAB ): FY GAAP EPS of -$4.63 beats by $0.30 . Revenue of $215M (+49.0% Y/Y) misses by $1.4M . As of December 31, 2022, cash and cash equivalents, short-term investments and restricted cash totaled $1,009.3 million, compared to $1,409.9 ...

Total revenue of $215.0 million for 2022, representing a 49.0% increase y-o-y; ZEJULA ® achieved 55.2% y-o-y growth Strong balance sheet with a cash position of $1.0 billion as of December 31, 2022 Company to host conference call and webcast on March 2, 2023, at 8:00 ...

SHANGHAI and CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), today announced that members of the company’s senior management team will participate in the following investor conferences in March 2023: Jefferies 2023 Biotech on the Bay ...

SHANGHAI, China and CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present two oral presentations highlighting the ad hoc interim overall survival (OS) study results of ZEJULA ® (niraparib) from the NORA Phase 3 study and a post hoc an...

SHANGHAI and CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the National Medical Products Administration (NMPA) in China has accepted the New Drug Application (NDA) for sulbactam-durlobactam (SUL-DUR), an investigational drug th...

Zai Lab Limited (ZLAB) Citi Biotech C-Suite Fireside Chat Series Conference Call February 14, 2023 11:00 AM ET Company Participants Josh Smiley - COO Conference Call Participants Yigal Nochomovitz - Citi Presentation Yigal Nochomovitz Okay, grea...

SHANGHAI and CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), today announced that it will report financial results and corporate updates for the twelve months ended December 31, 2022, after the closing of the U.S. equity markets on March 1, 2023. Th...

SHANGHAI and CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), today announced that members of the company’s senior management team will participate in the following investor conferences in February 2023: Guggenheim Oncology Conference ...

China's National Medical Products Administration (NMPA) granted priority review to Zai Lab's ( NASDAQ: ZLAB ) new drug application seeking approval of sulbactam-durlobactam (SUL-DUR) to treat infections caused by Acinetobacter baumannii, including multidrug-resistant and carbapen...